Should prostate cancer genomic classifiers, such as Decipher, be used in all high risk post-prostatectomy patients to risk stratify patients to adjvant RT vs PSA observation and possible salvage RT?

The optimal timing of post-prostatectomy RT in high-risk patients is debatable and currently the question of prospective randomized trials; however, given the recent JCO article by Den et al (3/10/15) regarding the benefit of the genomic classifier Decipher, should this be the standard method of determining whether adjuvant RT vs. salvage RT should be utilized in this high-risk cohort?